糖尿病大血管并发症防治的调脂策略课件.pptVIP

Results—Primary End Point: Event-free Survival Curves This slide illustrates the primary end point–cumulative event rates for all 3 treatment groups. The primary end point was the percent of unique patients with at least one major adverse CV event during the trial. This means that the first time a patient had any one of the composite events, they were counted once, regardless of whether they had another event thereafter. Major adverse CV events, the primary efficacy measure, occurred in: 151 placebo patients 110 NORVASC patients; risk reduction of 31% vs placebo (P=0.003) 136 enalapril pat